ArticleCureus2026
Clinical Value of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Neuroendocrine Neoplasms: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors in which functional imaging plays a central role in diagnosis, staging, and prognostic stratification. While somatostatin receptor (SSRs)-based imaging remains the standard for well-differentiated tumors, ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) provides complementary information on tumor metabolism and aggressiveness. We present the case of a 52-year-old male diagnosed in 2013 with a low-grade pancreatic neuroendocrine tumor who underwent surgical resection followed by multiple reinterventions due to local progression and mesenteric metastases. Serial SSR PET/CT studies demonstrated high receptor expression in mesenteric lesions. However, subsequent ¹⁸F-FDG-PET/CT revealed a hypermetabolic mesenteric nodal conglomerate, suggesting heterogeneous metabolic behavior and possible tumor dedifferentiation. This case highlights the clinical value of ¹⁸F-FDG-PET/CT in low-grade NENs, particularly for assessing disease progression, by providing prognostic information beyond histological grading alone. ¹⁸F-FDG-PET/CT may identify aggressive tumor components not evident on receptor-based imaging, supporting its role as a complementary tool in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.